Brief: Veracyte Q3 Revenue USD 115.9 Million Vs. IBES Estimate USD 109.8 Million
06/11/2024 21:05
Nov 06 (Reuters) - Veracyte Q3 gross margin 68%. * Q3 adjusted operating expenses USD 57.6 million * Q3 net income USD 15.2 million * outlook FY revenue USD 442-445 million * outlook FY revenue growth 22-23%
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina